Summary: We are writing to express concern
about the use of a recombinant
adenovirus type-5 (Ad5) vector for
a COVID-19 phase 1 vaccine study,1
and subsequent advanced trials.
Over a decade ago, we completed the
Step and Phambili phase 2b studies
that evaluated an Ad5 vectored
HIV-1 vaccine administered in three
immunisations for efficacy against
HIV-1 acquisition.2,3 Both international
studies found an increased risk of
HIV-1 acquisition among vaccinated
men.2,4
10
Average: 10 (1 vote)
Covid 19HIVLetterCovid 19 vaccine
CORRESPONDENCE| VOLUME 396, ISSUE 10260, E68-E69, OCTOBER 31, 2020
Published:October 19, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32156-5
We are writing to express concern about the use of a recombinant adenovirus type-5 (Ad5) vector for a COVID-19 phase 1 vaccine study,1 and subsequent advanced trials. Over a decade ago, we completed the Step and Phambili phase 2b studies that evaluated an Ad5 vectored HIV-1 vaccine administered in three immunisations for efficacy against HIV-1 acquisition.2,3 Both international studies found an increased risk of HIV-1 acquisition among vaccinated men.2,4
https://doi.org/10.1016/S0140-6736(20)32156-5